78 articles for AP Combs
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology.
Incyte
Synthesis and structure-activity relationships of pyrido[3,2-b]pyrazin-3(4H)-ones and pteridin-7(8H)-ones as corticotropin-releasing factor-1 receptor antagonists.
Bristol-Myers Squibb
Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model.
Incyte
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
Bristol-Myers Squibb
Synthesis and in vivo evaluation of cyclic diaminopropane BACE-1 inhibitors.
Bristol-Myers Squibb Research and Development
Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer.
Incyte
Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists.
Bristol-Myers Squibb
Potent benzimidazole sulfonamide protein tyrosine phosphatase 1B inhibitors containing the heterocyclic (S)-isothiazolidinone phosphotyrosine mimetic.
Incyte
Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.
Bristol-Myers Squibb Pharmaceutical Research Institute
Structure-based design and discovery of protein tyrosine phosphatase inhibitors incorporating novel isothiazolidinone heterocyclic phosphotyrosine mimetics.
Incyte
Synthesis, structure-activity relationships, and in vivo properties of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as corticotropin-releasing factor-1 receptor antagonists.
Bristol-Myers Squibb Pharmaceutical Research Institute
Parallel synthesis of potent, pyrazole-based inhibitors of Helicobacter pylori dihydroorotate dehydrogenase.
Bristol-Myers Squibb
INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ).
Incyte
Thienopyridinyl and thiazolopyridinyl compounds useful as IRAK4 inhibitors
Bristol-Myers Squibb
TRIAZINE DIONE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE
Jiangsu Hengrui Pharmaceuticals
Heterocyclic compounds, preparation methods therefor, and methods of uses thereof
Inventisbio
5-membered and bicyclic heterocyclic amides as inhibitors of ROCK
Bristol-Myers Squibb
Aryl-phosphorus-oxygen compound as EGFR kinase inhibitor
Chia Tai Tianqing Pharmaceutical Group
2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof
Beijing Scitech Mq Pharmaceuticals
Substituted heterocyclyl derivatives as CDK inhibitors
Aurigene Discovery Technologies
Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
Sanofi
Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
Poxel
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
Arvinas Operations
Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine
Kronos Bio
2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
Array Biopharma
Synthesis and dual D2 and 5-HT1A receptor binding affinities of 5-piperidinyl and 5-piperazinyl-1H-benzo[d]imidazol-2(3H)-ones.
King Fahd University of Petroleum & Minerals
Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
Tolero Pharmaceuticals
Kinetic and in silico analysis of thiazolidin-based inhibitors of a-carbonic anhydrase isoenzymes.
Ondokuz Mayis University
Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase
Merck Patent
Hetarylcoumarins: Synthesis and biological evaluation as potent a-glucosidase inhibitors.
Kinnaird College For Women
Inhibition of the ribonuclease H activity of HIV-1 reverse transcriptase by GSK5750 correlates with slow enzyme-inhibitor dissociation.
Mcgill University
New hybrid molecules combining benzothiophene or benzofuran with rhodanine as dual COX-1/2 and 5-LOX inhibitors: Synthesis, biological evaluation and docking study.
Alexandria University
C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
Merck Sharp & Dohme
Novel biphenyl bis-sulfonamides as acetyl and butyrylcholinesterase inhibitors: Synthesis, biological evaluation and molecular modeling studies.
Government College University
Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies
Galderma Research & Development
Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core
Boehringer Ingelheim International
Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
Astrazeneca
Pharmacological characterization of KUR-1246, a selective uterine relaxant.
Kissei Pharmaceutical
Design and synthesis of conformationally constrained cyclophilin inhibitors showing a cyclosporin-A phenotype in C. elegans.
The University of Edinburgh
Heteroaryl substituted pyridyl compounds useful as kinase modulators
Bristol-Myers Squibb
Benzenesulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (RORγ(T))
Galderma Research & Development
2-cyano-3-cyclopropyl-3-hydroxy-N-aryl-thioacrylamide derivatives
Algiax Pharmaceuticals
DISCOVERY AND STRUCTURE-ACTIVITY STUDIES OF A NOVEL SERIES OF PYRIDO[2,3-d]PYRIMIDINE TYROSINE KINASE INHIBITORS
Parke-Davis Pharmaceutical Research